Fat Loss and Metabolic Research Protocols
Fat loss research protocols group compounds that act on appetite signaling, lipolysis, and mitochondrial fuel handling. The stack below is the combination this tool recommends when fat loss is the selected research goal.
The science behind this category
Most of the published literature in this category splits into two mechanisms. Incretin receptor agonists slow gastric emptying and act on hypothalamic appetite circuits, which reduces energy intake. Lipolytic and mitochondrial agents instead act on how stored fat is mobilized and how efficiently the cell oxidizes it.
Because those mechanisms are separate, research protocols often pair one signaling agent with one metabolic agent rather than stacking two compounds that hit the same receptor family. Overlapping agonists rarely add effect and complicate interpretation of results.
Body composition studies in this space almost always run alongside a controlled protein intake and resistance training variable, because lean mass retention is the outcome that separates a useful metabolic result from simple weight reduction.
Appetite signaling is the most heavily documented arm of this category. Incretin receptor agonists were characterized first through their effect on glucose dependent insulin release, and only later through the central satiety signaling that drives the body composition outcomes reported in trials. That distinction matters when reading the literature, because glycemic endpoints and weight endpoints come from different mechanisms operating in the same molecule.
The lipolytic arm is smaller and mostly preclinical. Fragment analogs of growth hormone were studied specifically because they retain the fat mobilizing portion of the parent molecule while showing little of the effect on insulin sensitivity or tissue growth, which is why the research interest sits on adipose tissue rather than systemic anabolism.
Mitochondrial compounds sit in a third group. Rather than changing how much fuel enters the system, they are studied for how efficiently the cell converts substrate to usable energy, which shows up in the literature as changes in oxidative capacity and exercise tolerance rather than as direct weight change.
Read across all three groups, the reported ranges vary widely because study populations vary widely. Trial cohorts differ in baseline metabolic state, and outcome measures range from scale weight to DEXA derived lean and fat mass. The ranges on each compound page reflect what those specific studies reported, not a general recommendation.
Recommended research stack
Retatrutide30MG
GIP/GLP-1/glucagon triple receptor agonist
A triple-receptor incretin analog reported to produce the largest weight reductions seen in this class of research compounds.
Tesamorelin10MG
Stabilized GHRH analog
The only GHRH analog with published trial data specifically targeting visceral adipose tissue reduction.
AOD-960410MG
Modified hGH fragment (176-191)
A growth-hormone fragment studied for lipolytic activity without the glucose-handling effects of full-length hGH.
- Retatrutide 30MG $185.00
- Tesamorelin 10MG $72.00
- AOD-9604 10MG $80.00
Frequently asked questions
Which peptides are studied for fat loss / metabolic research?
The compounds this tool surfaces for this goal are Retatrutide, Tesamorelin, AOD-9604. Each one has its own profile page covering mechanism, what published studies measured, and the low, optimal and high ranges those studies reported. This is a summary of literature, not a recommendation for use.
How is a research stack for this goal structured?
Stacks in this category pair compounds that act through different mechanisms rather than stacking two agents that hit the same receptor family, so each variable can be read independently. The Protocol Builder returns an optimal tier and a lower cost comparable tier, and study blocks in the literature are run for a fixed duration with measurements at set intervals rather than continuously.
What does reconstitution involve?
Research compounds ship as lyophilized powder and are reconstituted with bacteriostatic water. The volume of diluent added sets the concentration, which in turn sets how many insulin syringe units correspond to a given amount. The reconstitution calculator on this site does that math, and the handling guide covers storage, stability and sterile technique.
Where are these compounds sourced?
The compounds referenced on this page are sold by ENOS Labs USA. Pepbuilder is a reference tool only and does not sell, ship or handle payment for any product. Everything referenced is for laboratory research use only and is not for human or veterinary consumption.
What compounds appear in a fat loss research stack?
Typically one incretin receptor agonist plus one metabolic or lipolytic agent, and often a mitochondrial compound. The builder ranks them by how strongly each maps to the selected goal.
Why combine an appetite pathway compound with a metabolic one?
They act on different targets. One reduces energy intake through receptor signaling in the gut and brain, the other affects how the cell handles fuel. Research protocols separate the two so each variable can be read independently.
How long do published research blocks usually run?
Trial designs in this area commonly report outcomes over 12 to 72 weeks, with body composition endpoints measured at fixed intervals rather than continuously.
Can I change the recommended stack?
Yes. The builder produces a starting stack from your selected goals, and you can select multiple goals to weight the recommendation differently.
Other research goals
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.